New data could change liquid biopsy guidelines and boost sales, though regulatory approval would not be a bad idea.
The data are positive, but might not do much for the company’s sales.
Syncona might have hoped for a bigger payday with the prostate imaging specialist, but it has plenty more irons in the fire.
Blood tests could be faster and cheaper than tissue biopsies, but a Thermo Fisher exec argues they are likely to be more of an add-on technique.
A new player has entered the liquid biopsy game.
The US FDA granted seven approvals in two days last week, including an eagerly awaited thumbs-up for Novartis’s gene therapy Zolgensma.
Two closely-watched liquid biopsy developers are to present data on their respective solid tumour blood tests.
The mere possibility of Guardant horning in on colorectal cancer has spooked Exact’s investors.
The cancer blood testing company Laboratory for Advanced Medicine is ready to compete on price, which might be necessary in a market already thronged with products.